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Abstract
Introduction: Patients with active acromegaly have 2- to 3-fold increased cardiovascular mortality. Alterations of acute phase proteins,
observed in acromegaly, could lead to cardiovascular diseases. Aim of the study was to evaluate fibrinogen and C-reactive protein (CRP)
secretion in patients with acromegaly.
Material and methods: Seventy-seven patients were divided into groups with active (AA, n = 56) and controlled acromegaly (CA, n = 21).
Twenty age- and sex-matched healthy subjects served as controls. Serum fibrinogen, CRP, fasting glucose, insulin, total cholesterol, LDL
and HDL cholesterol, and triglycerides were measured, and body mass index (BMI) was calculated.
Results: Comparison between the groups revealed: higher fibrinogen, triglycerides, glucose levels, and BMI values in AA than in the
controls; higher CRP, fibrinogen, triglyceride levels, and BMI values in CA than in the controls; higher LDL cholesterol and insulin levels
and lower CRP levels and BMI values in the AA group than in the CA group. Fibrinogen concentration was highest in the AA group and
lowest in the control group. Fibrinogen levels were high in all patients with acromegaly, irrespective of disease status, and they were
significantly higher than in healthy subjects. CRP concentration was highest in the CA group and lowest in the control group. CRP levels
were significantly and paradoxically lower in patients with AA than in patients with well-controlled disease and did not explain the
increased cardiovascular mortality in acromegaly.
Conclusions: Fibrinogen plays an important role as a cardiovascular risk factor in acromegaly, irrespective of the cure of the disease. The
role of CRP as a cardiovascular risk factor in patients with uncontrolled acromegaly should be better explained in future studies.
(Pol J Endocrinol 2010; 61 (1): 83–88)
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Streszczenie
Wstęp: U chorych na akromegalię stwierdza się 2–3-krotnie zwiększoną śmiertelność z przyczyn sercowo-naczyniowych. Zmiany stężeń
białek ostrej fazy, obserwowane w akromegalii, mogą prowadzić do chorób układu krążenia. Celem pracy była ocena wydzielania fibry-
nogenu i białka C-reaktywnego (CRP, C-reactive protein) u chorych na akromegalię.
Materiał i metody: Siedemdziesiąt siedem osób chorych podzielono na grupy z aktywną (AA, n = 56) i kontrolowaną akromegalią (CA, n = 21),
20 zdrowych osób dopasowanych pod względem płci i wieku stanowiło grupę kontrolną. Oznaczono stężenia fibrynogenu, CRP, glukozy
na czczo, insuliny, cholesterolu całkowitego, cholesterolu frakcji LDL i frakcji HDL, triglicerydów w surowicy, oraz wyliczono wskaźnik
masy ciała (BMI, body mass index).
Wyniki: Porównanie badanych grup wykazało: większe stężenia fibrynogenu, triglicerydów, glukozy i wartości BMI w grupie AA niż
kontrolnej; większe stężenia CRP, fibrynogenu, triglicerydów i wartości BMI w grupie CA niż kontrolnej; większe stężenia cholesterolu
frakcji LDL i insuliny oraz mniejsze CRP i wartości BMI w grupie AA niż CA. Stężenie fibrynogenu było największe w grupie AA,
a najmniejsze w grupie kontrolnej. Było ono wysokie u wszystkich chorych na akromegalię, niezależnie od stadium choroby i istotnie
większe niż u osób zdrowych. Stężenie CRP było największe w grupie CA, a najmniejsze w grupie kontrolnej. Stężenia CRP były paradok-
salnie istotnie mniejsze w grupie AA niż w grupie CA i nie tłumaczą przyczyny zwiększonej śmiertelności z przyczyn krążeniowych
w akromegalii.
Wnioski: Fibrynogen odgrywa ważną rolę jako czynnik ryzyka sercowo-naczyniowego w akromegalii, niezależnie od wyleczenia choro-
by. Znaczenie CRP jako czynnika ryzyka krążeniowego u chorych z niewyrównaną akromegalią powinno być dokładniej wyjaśnione
w dalszych badaniach. (Endokrynol Pol 2010; 61 (1): 83–88)
Słowa kluczowe: akromegalia, fibrynogen, CRP, ryzyko sercowo-naczyniowe
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Introduction
Acromegaly is a rare disease leading to a 2- to 3-fold
increased in mortality from cardiovascular complica-
tions. It is associated with elevated growth hormone
(GH) levels [1–3]. Different metabolic changes, secon-
dary to GH and insulin-like growth factor 1 (IGF-1)
hypersecretion, favour atherogenic processes. Dyslipi-
daemia, diabetes mellitus, insulin resistance, and hy-
pophyseal hormone changes might initiate atheroscle-
rotic plaque creation, accelerate its progression, and
cause earlier occurrence of cardiovascular complications
[4]. An arterial wall low-grade inflammation, rising be-
fore structural changes, is believed to be the first step of
atherogenesis [5].
Acute phase reactants, like fibrinogen and high sen-
sitivity C-reactive protein (hs-CRP), are well-known car-
diovascular risk (CVR) factors. CRP exerts ability of di-
rect initiation and development of both atheromatosis
and endothelial inflammation, by the influence on ni-
tric oxide and cytokines secretion, and on adhesive
molecules expression [6, 7]. Fibrinogen and other fac-
tors involved in the clotting process are associated with
cardiovascular diseases. Fibrinogen has an atherogenic
effect, although there is a question whether chronic in-
flammation and atheromatosis also cause hyperfibrino-
genaemia [8, 9].
There are limited data on the influence of GH and
IGF-1 excess on acute phase reactants. The data on both
CRP [10, 11] and fibrinogen [10, 12-14] levels in acro-
megaly are controversial.
The aim of the study was to evaluate selected acute
phase proteins levels: fibrinogen and C-reactive prote-
in (CRP), in patients with acromegaly.
Material and methods
Subjects
Seventy-seven acromegalic patients were included in
the study. They were divided into two groups according
to minimal GH during oral glucose (75 g) tolerance test
and IGF-1 concentrations. In the active acromegaly gro-
up (AA) 56 patients with GH concentration ≥ 1 µg/L
or/and IGF-1 concentration above normal for their age
and sex range were included. In the well-controlled
acromegalic group (CA) 21 patients with GH concen-
tration < 1 µg/L and normal IGF-1 concentration for
their age and sex range were included. Twenty sex-
matched healthy subjects served as the control group.
The clinical characteristics of the studied subjects are
shown in Table I.
Methods
All study participants were examined for their body
mass and height, and body mass index (BMI) was cal-
culated. In all subjects blood samples were taken for
hormonal and laboratory analyses after an overnight
fast. The following parameters were measured: fibrino-
Table I. Clinical characteristics of the subjects
Tabela I. Kliniczna charakterystyka badanych
Parameter Group Mean SD Median Quartiles 25%/75%
Age (years) AA 51.42 14.56 53.00 38.00/65.00
CA 53.19 8.98 54.00 51.00/60.00
CG 45.65 11.58 50.50 35.00/55.00
Height [cm] AA 169.00 0.10 167.50 162.00/165.00
CA 165.00 0.10 164.00 159.00/170.00
CG 168.00 0.10 168.00 158.50/176.00
Body mass [kg] AA 81.80 15.99 83.50 71.00/94.00
CA 84.58 16.90 78.70 75.00/91.00
CG 70.95 13.16 73.00 56.50/82.00
BMI [kg/m2] AA 28.39 3.99 28.62 25.82/31.71
CA 30.95 5.81 29.41 26.22/34.41
CG 24.88 3.45 25.10 21.37/27.75
Time since first symptoms (years) AA 15.91 9.58 15.00 10.00/20.00
CA 15.61 9.15 13.50 10.00/21.00
Time since diagnosis (years) AA 8.89 8.76 7.00 1.00/13.00
CA 8.27 7.33 7.50 3.00/11.50
SD — standard deviation; BMI — body mass index; AA — active acromegaly; CA — controlled acromegaly; CG — control group
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gen, CRP, fasting glucose, insulin, total cholesterol, LDL
and HDL cholesterol, and triglycerides. Patients were
asked to report the period of the symptoms and the time
from diagnosis.
The following analytical methods were applied:
GH — DPC Biermann GmbH, Bad Nauheim, Germa-
ny — ELISA; IGF-1 — BioSource IGF-I-D-RIA-CT Kit,
BioSource Europe, Nivelles, Belgium –— RIA; Fibrino-
gen — Dade Behring Marburg GmbH, Marburg, Ger-
many — Claus modified method; hs-CRP — DPC Bier-
mann GmbH, Bad Nauheim, Germany — ELISA; glu-
cose — hexokinase method; Insulin — DPC Biermann
GmbH, Bad Nauheim, Germany — ELISA; Total chole-
sterol — Cholesterol RTU BioMerieux, Lyon, France
— enzymatic method; LDL cholesterol — calculated
from Friedewald’s formula; HDL cholesterol — HDL
Cholesterol Direct, BioMerieux, Lyon, France — enzy-
matic method; Triglycerides — Triglycerides Enzyma-
tique PAP 150, BioMerieux, Lyon, France — enzymatic
method.
Statistical analysis
Parameter distribution was assessed using Shapiro-
Wilk’s W-test. Mann-Whitney’s U-test was used for cal-
culation of the statistically significant differences. Pear-
son’s test was used for calculation of the correlations.
The level of statistical significance was set at a level of
p-value < 0.05. In some cases, the borderline statistical
significance at p-value level between 0.10 and 0.05 was
considered.
Results
We observed statistically significant: higher fibrinogen,
triglycerides, glucose levels, and BMI values in the AA
group than in the controls (p < 0.00001, 0.002, 0.01, and
0.001, respectively); higher CRP, fibrinogen, triglyceri-
des levels, and BMI values in the CA group than in the
controls (p < 0.01, 0.002, 0.04, and 0.001, respectively);
higher LDL cholesterol and insulin levels and lower CRP
levels and BMI values in the AA group than in the CA
groups (p < 0.04, 0.02, 0.05, and 0.03, respectively).
Mean serum fibrinogen concentration was highest
in the AA group and lowest in the control group. The
differences in fibrinogen concentrations between the AA
and control groups, and between the CA and control
group, were statistically significant (p <0.00001 and
p <0.002, respectively). There was no difference betwe-
en the AA and CA groups (Table II, Fig. 1).
Mean serum hs-CRP concentration was highest in
the CA group and lowest in the control group. The dif-
ferences in hs-CRP concentrations between the AA and
CA groups, and between the CA and control groups,
were statistically significant (p < 0.05, p < 0.01, respec-
tively). There was no difference between the AA and
control groups (Table II, Fig. 2).
Positive, statistically significant correlation betwe-
en minimal GH (after OGTT) and concentrations of glu-
cose, insulin, triglycerides, and body mass was docu-
mented in the AA group. Borderline positive correla-
tion between minimal GH and fibrinogen concentra-
tions was observed in this group. Negative correlations
in the AA group were shown between minimal GH and
HDL cholesterol concentration. There was a borderline
negative correlation between minimal GH and hs-CRP
concentrations in this group (Table III).
In the AA group, positive correlations between IGF-
1 and insulin, triglycerides concentrations, and body
mass were shown, and negative correlations between
IGF-1 and HDL cholesterol and hs-CRP (Table IV). In
the CA group, negative correlations between IGF-1 and
hs-CRP and age were shown (Table IV).
Moreover, in the AA group, positive correlations
between body mass and insulin and fibrinogen concen-
trations were observed (not shown). Both in the AA and
CA groups, a positive correlation between BMI and fi-
brinogen was observed (not shown).
Discussion
Fibrinogen is a well-known and widely described acu-
te phase reactant and cardiovascular risk factor. Its me-
tabolites can cause endothelium damage and dysfunc-
tion. Fibrinogen can initiate atherosclerotic plaque cre-
ation, accelerates its progression, and causes earlier car-
diovascular complications to arise [8, 9].
We observed statistically significant higher fibrino-
gen levels both in active and cured acromegaly patients
than in controls. This could suggest exaggerated throm-
bo- and atherogenic processes in acromegaly, but it is
yet to be clarified whether higher fibrinogen level is
a primary cause or is secondary to atheromatosis and
endothelial dysfunction [8, 9]. The weak, borderline
correlation between minimal GH and fibrinogen levels
in active acromegaly indicates the possible influence of
elevated GH concentrations on fibrinogen concentra-
tions; no such correlation was found in cured acromega-
ly patients. In our study, fibrinogen levels were highest
in active acromegaly patients, but they did not differ si-
gnificantly from those in cured acromegaly patients.
There is some controversy regarding fibrinogen con-
centrations in acromegaly. In some studies fibrinogen
levels were higher in patients with acromegaly than in
healthy subjects [12–14]. They were lower in cured than
in non-cured acromegalics, but they were higher than
in healthy controls [12]. By way of contrast, in another
study fibrinogen concentrations did not differ between
active and cured acromegalics [10].
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Table II. Concentrations of minimal GH, IGF-1, hsCRP, fibrinogen, lipids, insulin, and glucose in the groups studied
Tabela II. Stężenie GH, IGF-1, hs-CRP, fibrynogenu, lipidów, insuliny i glukozy w badanych grupach
Parameter Group Mean SD Median Quartiles 25%/75%
Minimal GH [µg/L] AA 5.15 7.61 2.75 1.01/6.86
CA 0.43 0.29 0.43 0.18/0.55
CG 0.34 0.36 0.14 0.07/0.64
IGF-1 [ng/ml] AA 818.85 510.99 644.90 412.95/1120.20
CA 260.83 83.61 259.65 231.30/285.90
CG 315.00 70.59 308.20 267.80/365.40
hs-CRP [mg/L] AA 0.78 0.95 0.35 0.16/0.96
CA 1.16 0.89 0.96 0.67/1.31
CG 0.67 0.74 0.41 0.16/0.66
Fibrinogen [mg/dL] AA 409.00 88.57 435.00 335.00/480.00
CA 398.24 108.12 380.00 330.00/500.00
CG 289.50 62.45 285.00 245.00/325.00
Fasting glucose [mg/dL] AA 98.78 16.62 95.00 88.00/106.00
CA 94.75 21.07 88.50 81.50/105.50
CG 88.95 6.48 88.50 84.50/94.00
Insulin (mIU/ml) AA 9.37 6.76 7.60 4.85/11.10
CA 5.86 2.90 6.30 3.50/7.60
CG 7.16 2.13 7.65 5.80/8.65
Total cholesterol [mg/dL] AA 217.33 42.68 213.50 195.00/227.00
CA 214.72 37.37 210.00 187.00/239.00
CG 212.45 27.26 213.5 195.00/227.00
LDL cholesterol [mg/dL] AA 136.6 33.11 130.50 115.50/158.50
CA 126.94 40.55 121.00 91.00/138.00
CG 132.75 28.44 131.50 109.5/146.00
HDL cholesterol [mg/dL] AA 58.16 14.80 57.50 47.00/66.50
CA 66.41 27.91 65.00 53.00/76.00
CG 66.15 20.91 57.00 55.50/70.00
Triglycerides [mg/dL] AA 124.91 55.10 112.00 86.00/160.00
CA 117.50 67.88 100.00 80.00/138.00
CG 87.85 42.89 74.50 60.50/101.50
GH — growth hormone; IGF-1 — insulin growth factor 1; hs-CRP — high selection C-reactive protein; AA — active acromegaly; CA — controlled
acromegaly; CG — control group
Figure 1. Mean serum fibrinogen concentrations in the groups
studied. AA — active acromegaly; CA — controlled acromegaly;
CG — control group
Rycina 1. Średnie stężenie fibrynogenu w badanych grupach.
AA — aktywna akromegalia; CA — kontrolowana akromegalia;
CG — grupa kontrolna
Figure 2. Mean serum hs-CRP concentrations in the groups
studied. AA — active acromegaly; CA — controlled acromegaly;
CG — control group
Rycina 2. Średnie stężenie hs-CRP w surowicy w badanych
grupach. AA — aktywna akromegalia; CA — kontrolowana
akromegalia; CG — grupa kontrolna
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Colao et al. observed a decrease of fibrinogen le-
vels in a smaller group of patients with recently dia-
gnosed acromegaly without lipid disorders and hyper-
tension after 6 months of somatostatin analogue (lan-
reotide) therapy. Similarly to our study, they showed
the highest reduction of fibrinogen levels in patients
with better control of acromegaly (greater GH suppres-
sion) [12]. Hekimsoy et al. studied biochemical CVR
factors, including fibrinogen, in patients with good and
weak control of acromegaly. They did not show, like
us, any significant differences between fibrinogen con-
centrations in both groups of patients [10]. On the
other hand, Sartorio and co-workers presented higher
fibrinogen levels in acromegaly than in GH deficiency
(GHD), and higher fibrinogen in GHD than in con-
trols [14].
The latter observation is a very important one, since
both GH excess and GHD could have a similar negati-
ve and harmful effect on CVR [15, 16]. In the current
study, GHD was studied neither in cured acromegaly
nor in the control group; we can only speculate that
some patients with controlled acromegaly could be GH
deficient subjects. The values of minimal GH levels in
our cured patients could support this suspicion. More-
over, recent data from literature has documented nu-
merous cases of GHD in patients with successfully tre-
ated acromegaly [17].
The discrepancies among the various above-men-
tioned studies could be also explained by several fac-
tors such as lipid levels, hypertension, smoking habits,
or other hormonal deficiencies. Another differentiating
factor might be the criterion of disease cure. We have,
for that reason, applied GH concentration suppression
< 1 µg/L following OGTT (75 g) as a very strict criterion
of cure, according to the recent European and Ameri-
can standards [18–20]. Data from literature point to-
wards a reduction of mortality in acromegaly when the
mean GH was reduced to < 2.5 µg/L [3, 21–24]. Only one
study indicated mortality reduction when GH < 1 µg/L,
although increased mortality was also associated with
GHD [2]. Finally, the application of more strict criteria
of acromegaly cure, as used by us, would increase the
number of GHD cases that can blur mortality analysis.
High-sensitivity CRP is another well-known, mo-
dern, and widely approved CVR factor [6, 7, 25]. It plays
a crucial role in arterial wall low-grade inflammation,
which is believed to be the first step of atherosclerotic
plaque creation, just before structural changes. In the
current study, CRP levels were paradoxically lowest in
patients with active acromegaly and in healthy subjects
from the control group. This could imply low CVR in
patients with active acromegaly. Concentrations of hs-
CRP in cured acromegalic patients were higher than in
patients with active acromegaly and in controls. The
presence of lower hs-CRP levels in active than in well-
controlled acromegaly, and similar to healthy subjects,
is surprising. This needs to be extensively studied in
the future.
The results of the CRP studies in acromegaly are still
unequivocal. Some authors reported low CRP levels in
active acromegaly, and their increase followed acrome-
galy control during GH receptor antagonist (pegviso-
mant) therapy [11]. Other studies did not reveal signifi-
cant differences between patients with active and con-
trolled acromegaly [10].
CRP exacerbates arterial atheromatosis by worse-
ning endothelial function [7], and hs-CRP is conside-
red a strong and independent CVR factor [25]. Never-
theless, the relation of the atheromatosis extent to hs-
CRP concentration was not clearly documented [26].
CRP is produced in the liver by activated monocytes
under the influence of cytokines [27]. GH acts by means
Table III. Correlations between minimal serum GH
concentrations and other parameters in patients with active
acromegaly (AA)
Tabela III. Korelacje między stężeniem GH w surowicy
i innymi parametrami u chorych na aktywną akromegalię (AA)
Group Parameter Correlation p-value
coefficient r
AA Insulin +0.67 < 0.0001
AA Glucose +0.51 < 0.0001
AA hs-CRP –0.28 0.08
AA Fibrinogen +0.27 0.09
AA TG +0.38 < 0.01
AA HDL –0.29 < 0.05
AA Body mass +0.35 < 0.01
Table IV. Correlations between serum IGF-1 concentrationand
other parameters in patients withacromegaly
Tabela IV. Korelacje między stężeniem IGF-1 w surowicy
a innymi parametrami u chorych na akromegalię
Group Parameter Correlation p value
coefficient
AA Body mass +0.37 < 0.01
AA Insulin +0.54 < 0.0001
AA TG +0.39 < 0.01
AA HDL –0.29 < 0.05
AA hs-CRP –0.34 < 0.05
CA Age –0.46 < 0.05
CA hs-CRP –0.54 < 0.05
TG — triglyceride; AA — active acromegaly; CA — controlled
acromegaly
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of GH receptors belonging to the cytokine receptor su-
perfamily, and GH receptor activation induces molecular
signalling similar to cytokine signalling [28]. High GH con-
centrations can compete with proinflammation cytokines,
and in such a way can decrease hs-CRP levels [29]. This
may lead to the conclusion that GH protects endothelium
and arterial wall. The mechanisms of this process remain
unexplained. More data and future studies are necessary.
In another study, acute phase reactants were higher
in GHD patients than in healthy controls, and their le-
vels decreased following GH administration [30]. In our
subjects, GHD was not studied, but we could asume GHD
in some of our patients with controlled acromegaly. This
might explain higher hs-CRP in this group. Other au-
thors had similar observations to ours, confirmed by the
correlations of hs-CRP with GH and IGF-1 [31, 32].
Another explanation of the differences in hs-CRP
among our groups could be adipose tissue mass. GH
exerts lipolytic activity, and fat mass in cured acrome-
galy is higher than in active acromegaly. There were
negative correlations between hs-CRP and BMI in acti-
ve acromegaly patients. Adipose tissue possesses GH
receptors, and it is a source of IL-6 production, which
stimulates CRP synthesis [33]. We can speculate that
GH inhibits IL-6 synthesis and decreases CRP secretion.
This hypothesis has not been confirmed and should be
explained in future studies.
In summary of the presented results, we have clear-
ly documented that fibrinogen concentrations in all
patients with acromegaly were significantly higher than
in healthy subjects, irrespective of disease status. This
could indicate fibrinogen as an important CVR factor
in acromegaly. Levels of another widely accepted risk
factor — CRP — were significantly and paradoxically
lower in patients with active acromegaly than in pa-
tients with well controlled disease and did not explain
the increased cardiovascular mortality in acromegaly.
Conclusions
Fibrinogen plays an important role as a cardiovascular
risk factor in acromegaly, irrespective of the cure of the
disease. The role of CRP as a cardiovascular risk factor
in patients with uncontrolled acromegaly needs to be
better explained in future studies.
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